- Conditions
- Asthma
- Interventions
- placebo, risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 20
- States / cities
- Costa Mesa, California • Mountain View, California • Centennial, Colorado + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 313–336
of 673
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Atrial Fibrillation
- Interventions
- Not listed
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25,586 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Lexington, Massachusetts
- Conditions
- Scleroderma, Systemic
- Interventions
- Avenciguat (BI 685509), Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 16 more
- Conditions
- Neoplasms
- Interventions
- BI 765179, Ezabenlimab, Pembrolizumab
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Beverly Hills, California • Chapel Hill, North Carolina + 2 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 45
- States / cities
- Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more
- Conditions
- Dermatitis, Atopic
- Interventions
- BI 655130, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 6 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 1 Year to 40 Years
- Enrollment
- 11,296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Interventions
- BIBF 1120
- Drug
- Lead sponsor
- Patrick Y. Wen, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Cleveland, Ohio • Charlottesville, Virginia
- Conditions
- Atrial Fibrillation, Hemorrhage
- Interventions
- Dabigatran 75 mg, Dabigatran 150 mg
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Brooklyn, New York • Stony Brook, New York + 1 more
- Conditions
- Enhance Delineation of the Stomach Anatomy and the Surgeon's Appreciation of the Extent of Gastric Volume to be Removed;, Increase the Safety Profile of the Patient (i.e., Reduce the Likelihood of Accidental Stapling of the Orogastric Tube or Bougie);, Reduce the Incidence of OR Contamination/Infection Transmission;, Streamline OR Workflow, Resulting in Reduced OR Time, Ensure Consistent and Reproducible Staple Lines.
- Interventions
- Utilization of ViSiGi calibration tube, Usual non suction Bougie
- Device
- Lead sponsor
- St. Luke's Hospital and Health Network, Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Allentown, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BI 1015550, Pirfenidone
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- The Woodlands, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- linagliptin QD (once daily) for 7 days
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 6
- States / cities
- Cypress, California • DeLand, Florida • Miami, Florida + 3 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium, HandiHaler, Respimat SMI
- Drug · Device
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • San Diego, California • San Jose, California + 7 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium bromide
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Nashville, Tennessee + 1 more
- Conditions
- Thromboembolism
- Interventions
- Dabigatran, Warfarin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,867 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 18
- States / cities
- Mobile, Alabama • Hartford, Connecticut • Clearwater, Florida + 15 more
- Conditions
- HIV Infections
- Interventions
- Nevirapine, Zidovudine
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • San Diego, California • Worcester, Massachusetts
- Conditions
- Lung Diseases, Interstitial
- Interventions
- Nintedanib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 25 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium Inhalation Solution, Placebo
- Drug · Other
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 983 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more
- Conditions
- Asthma
- Interventions
- Combivent® CFC MDI, Albuterol HFA MDI
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Lakewood, California • Palmdale, California + 23 more
- Conditions
- Obesity, Diabetes Mellitus, Type 2
- Interventions
- Survodutide, Placebo
- Combination Product
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 34
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Spring Valley, California + 31 more
- Conditions
- Depressive Disorder, Major
- Interventions
- 5 mg BI 1569912, Placebo matching BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 35
- States / cities
- Bellflower, California • Long Beach, California • Oceanside, California + 31 more
- Conditions
- HIV Infections
- Interventions
- Nevirapine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Months to 13 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 90
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, Exercise
- Interventions
- tiotropium 18 mcg, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 519 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 21
- States / cities
- Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more